News | February 21, 2011

FDA Approves Endoprosthesis on Lower Profile Delivery System

February 21, 2011 – The U.S. Food and Drug Administration has approved an endoprosthesis device for use on a lower profile delivery system. The Gore Viabahn Endoprosthesis with Heparin Bioactive Surface, from W.L. Gore and Associates, is designed to percutaneously treat peripheral artery disease by relining the native vessel.

The next generation device enables a reduction in delivery profile to 6 Fr for 5 and 6 mm devices and 7 Fr for 7 and 8 mm devices and is delivered over a 0.0180-inch or 0.014-inch guidewire. No changes have been made to the endoprosthesis. The reduced delivery profile will provide interventionalists with greater options for delivery with the same trackability and device performance in treating stenoses and occlusions of the superficial femoral artery (SFA) and iliac artery.

“While most technology has stagnated over the past several years, W. L. Gore continues to optimize the Gore Viabahn Endoprosthesis which allows physicians to broaden the potential patient population that we can treat,” said Gary Ansel, M.D., interventional cardiologist at Riverside Methodist Hospital, Columbus, Ohio.

The endoprosthesis with Heparin Bioactive Surface is the only stent-graft approved for use in the SFA and iliac artery. The new device is available with a 120-cm long delivery catheter and incorporates the Carmeda BioActive Surface (CBAS), which utilizes end-point immobilization of derivatized heparin to the endoprosthesis luminal surface. This surface preserves the heparin bioactive sites such that they remain free to interact with the blood at the device surface without being consumed.

The Gore Viabahn Endoprosthesis was introduced in the United States in 2001. The Endoprosthesis with Heparin Bioactive Surface was approved for use in the United States in 2007. The stent-graft is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The device’s flexibility enables it to better traverse tortuous areas of the SFA and iliac artery, allowing it to conform to these arteries and withstand complex mechanical motion.

For more information: www.goremedical.com

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD)| August 02, 2017
Aug.
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Gore Announces First-in-Human Use of Gore TAG Conformable Thoracic Stent Graft
News | Stent Grafts| July 17, 2017
W. L. Gore & Associates Inc. announced the first patient implant of the Gore TAG Conformable Thoracic Stent Graft...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Overlay Init